Expression of matrix metalloproteinase and its tissue inhibitor in haemangioma

Abstract

The action mechanism of matrix metalloproteinases-2 (MMP-2) and tissue inhibitor of metalloproteinases-2 (TIMP-2) in the genesis, development and degeneration of haemangioma was investigated by detecting their expression in the tissue of haemangioma in different phases by using the immunohistochemistry. Fifty paraffin-embedded specimens of skin capillary haemangioma were collected, which were documented in the Department of Pathology, Renmin Hospital of Wuhan University from 2000 to 2006. All samples were stained by regular HE method, and proliferative cell nuclear antigen (PCNA) was tested by immunohistochemical S-P method. The samples were classified according to the Mulliken criteria and the expression pattern of PCNA. Immunohistochemical S-P method was applied to detect the expression of MMP-2 and TIMP-2 in proliferative and degenerative phases of cutaneous capillary haemangioma, and in normal skin tissues. In combination with the detection of the expression of factor VIII-related antigen, it was verified that in haemangioma tissues, the cells expressing MMP-2 and TIMP-2 were vascular endothelial cells. The MMP-2 and TIMP-2 expression was quantitatively analyzed by image analysis system (HPIAS-1000), and one-way ANOVA(107) and SNK(q) test were done to analyze average absorbance (A) and positive area rate of immunohistochemically positive particles by using SPSS11.5. The results showed: (1) Among 50 samples of haemangioma, there were 26 proliferative haemangiomas, and 24 degenerative haemangiomas, respectively; (2) The expression of MMP-2 was weak in normal vascular endothelial cells, cytoplasm of connective tissues and extracellular matrix around blood vessels. The expression of MMP-2 in proliferative group was significantly higher than in degenerative group and control group (normal skin) (P<0.05), but there was no statistically significant difference between the latter two groups; (3) TIMP-2 was highly expressed in normal tissues, degenerative vascular endothelial cells, cytoplasm of connective tissues and extracellular matrix around blood vessels. The expression level of TIMP-2 in proliferative phase was significantly lower than in degenerative phase (P<0.05), and the expression of TIMP-2 in proliferative phase was significantly different from that in degenerative phase and normal tissues (P<0.05). It was concluded that in proliferative phase of haemangioma, MMP-2 may promote over-proliferation of endothelial cells of haemangioma, and in degenerative phase, TIMP-2 can inhibit the proliferation of endothelial cells of haemangioma. The two substances play important roles in the genesis, development and degeneration of haemangiomas.

Keywords

cutaneous haemangioma / matrix metalloproteinases-2 / tissue inhibitor of metalloproteinases-2 / immunohistochemistry

References

[1] RitterM.R., ButschekR.A., FriedlanderM., et al.. Pathogenesis of infantile haemangioma: new molecular and cellular insights. Expert Rev Mol Med, 2007, 9: 1-19

[2] SundineM.J., WirthG.A.. Haemangiomas: an overview. Clin Pediatr (Phila), 2007, 46(3): 206-221

[3] BaulandC.G., Van SteenselM.A., SteijlenP.M., et al.. The pathogenesis of haemangiomas: a review. Plast Reconstr Surg, 2006, 117(2): 29e-35e

[4] WilliamH., EliseL., EmmanuelleP., et al.. Beneficial and detrimental influences of tissue inhibitor of metalloproteinase-1 (TIMP-1) in tumor progression. Biochem, 2005, 87(3–4): 377-383

[5] NieQ.H., DuanG.R., XieY.M., et al.. Expression of TIMP-1 and TIMP-2 in rats with hepatic fibrosis. World J Gastroenterol, 2004, 10(1): 86-90

[6] FernándezC.A., ButterfieldC., JacksonG., et al.. Structural and functional uncoupling of the enzymatic and angiogenic inhibitory activities of tissue inhibitor of metalloproteinase-2 (TIMP-2): loop 6 is a novel angiogenesis inhibitor. J Biol Chem, 2003, 278(42): 40989-40995

[7] TunuguntlaR., Rip leyD., SangQ.X., et al.. Expression of matrix metalloproteinases-6 and tissue inhibitors of metalloproteinases TIMP-3 and - 4 in benign endometrium and endometrial cancer. Gynecol Oncol, 2003, 89(3): 453-464

[8] ShacoL.R., SharabiS., BenharrochD., et al.. Matrix metalloproteinases 2 and 9, E-caderin, and beta-catenin expression in endometriosis, low grade endometrial carcinoma and nonneoplasticentopic endometrium. Eur J Obstet Gynecol Reprod Biol, 2008, 139(2): 226-232

[9] FriedenI.J.. Is it a haemangioma or could it be cancer?. Pediatr Dermatol, 2006, 23: 402-403

[10] FriedenI.J., HaggstromA.N., DroletB.A., et al.. Infantile haemangiomas: current knowledge, future directions. Proceedings of a research workshop on infantile haemangiomas, April 7–9, 2005, Bethesda, Maryland, USA. Pediatr Dermatol, 2005, 22(5): 383-406

[11] FriedlanderS.F., RitterM.R., FriedlanderM.. Recent progress in our understanding of the pathogenesis of infantile haemangiomas. Lymphat Res Biol, 2005, 3(4): 219-225

[12] CarmelietP.. Angiogenesis in life, disease and medicine. Nature, 2005, 438(7070): 932-936

[13] YuY., Wylie-SearsJ., BoscoloE., et al.. Genomic imprinting of IGF2 is maintained in infantile haemangioma despite its high level of expression. Mol Med, 2004, 10(7–12): 117-123

[14] MarchukD.A.. Pathogenesis of haemangioma. J Clin Invest, 2001, 107(6): 665-666

[15] ColletteT., MaheuxR., MaillouxJ., et al.. Increased expression of matrix metallop roteinase-9 in the eutopic endometrial tissue of women with endometriosis. Hum Reprod, 2006, 21(12): 3059-3067

[16] HudelistG., LassH., EcksteinJ., et al.. Interleukin 1alpha and tissue-lytic matrix metallop roteinase-1 are elevated in ectopic endometrium of patients with endometriosis. Hum Reprod, 2005, 20(6): 1695-1701

[17] KimH.O., YangK.M., KangI.S., et al.. Expression of CD44s, vascular endothelial growth factor, matrixmetallop roteinase-2 and Ki-67 in peritoneal, rectovaginal and ovarian endometriosis. Reprod Med, 2007, 52(3): 207-213

[18] RamonL., GilahetE.J., CastelloR., et al.. Mrna analysis of several components of the plasminogen activator and matrix metalloproteinase systems in endometriosis using a realtime quantitative RT-PCR assay. Hum Reprod, 2005, 20(1): 272-278

[19] BoekerK.H., HaberkornC.I., MichelsD., et al.. Diagnostic potential of circulating TIMP1 and MMP-2 as marker of liver fibrosis in patients with chronic hepatitis C. Clin Chim Acta, 2002, 316: 71-81

[20] TaraholeniG., AscenzoS., BorsoltiG., et al.. Shedding of the matrix metalloproteinase-2, metalloproteinase-9 (MMP-2, MMP-9), and MT1-MMP as membrane vesicle assiciated components by endothilcells. Am J Pathol, 2002, 160(2): 673-677

[21] SiddiiiqueK., YanamandraN., GujratiM., et al.. Expressionof matrix metalloproteinases, their inhibitors, and urokinase plasminogen activator in human meningiomas. Cancer Res, 2006, 17(7): 555-566

[22] PaekS.H., KimC.Y., KimY.Y., et al.. Correlation of clinical and biological parameters with peritumoral edema in meningioma. Neurosurgery, 2005, 272(11): 146-151

[23] MurphyF., IssaR., ZhouX., et al.. Inhibition of apoptosis of activated hepatic stellate cells by TIMP-1 is mediated via effects on MMP in hibitin: Implications for reversibility of liver fibrosis. J Biol Chem, 2002, 277(13): 11 069-11 076

[24] MatsumotoE., NakatsukasaH., NousoK., et al.. Elevated levels of tissue inhibitor of metalloproteinases (TIMPS) in human hepatocellular carcinomas. Comp Hepatol, 2004, 3(Suppl1): S51

[25] PaulS., SharmaA.V., MahapatraP.D., et al.. Role of melatonin in regulating matrix metalloproteinase29 via tissue inhibitors of metalloproteinase-1 during protection against endometriosis. J Pineal Res, 2008, 44(4): 439-449

[26] BergmanM.R., TeerlinkJ.R., MahimkarR., et al.. Cardiac matrix metalloproteinase-2 expression independently in ducesmarked ventricular remodeling and systolic dysfunction. Am J Physiol Heart Circ Physiol, 2007, 292(4): H1847-H1860

This project was supported by a grant from the National Natural Sciences Foundation of China (No. 30872688).